Objective: The outcomes of patients with metastatic phaeochromocytoma (PHEO) and paraganglioma (PGL) are unclear. We performed a systematic review and metaanalysis of baseline characteristics and mortality rates of patients with metastatic PHEO and PGL (PPGL). Measurements: Reviewers extracted standardized data and assessed risk of bias using a modified Newcastle-Ottawa tool. Random-effects meta-analysis was used to pool event rates across studies.
| INTRODUCTION
Phaeochromocytoma (PHEO) and paraganglioma (PGL) are rare neuroendocrine tumours derived from chromaffin tissue of the adrenal medulla and extra-adrenal paraganglia, respectively. PHEO and PGL (PPGL) can occur sporadically or as inherited genetic syndromes, primarily multiple endocrine neoplasia type 2 (MEN2), von HippelLindau (VHL) disease, neurofibromatosis type 1 (NF1) and mutations in succinate dehydrogenase subunits (SDHx). [1] [2] [3] [4] Approximately 2%-13% of patients with PHEO and 2.4%-50% with PGL have been reported to have metastatic disease with differences mainly due to selection bias. [5] [6] [7] Reported survival rates of patients with metastatic PPGL vary considerably between studies, with 5-year survival rates ranging from 12% to 84%. 2, [8] [9] [10] [11] [12] Due to the rarity of this disease, variability of malignancy definitions, fragmented nature of studies and small numbers of patients, there is no clear and consistent documentation of the outcomes in patients with metastatic PPGL. Therefore, a more accurate survival estimation of patients with metastatic PPGL is warranted.
The aim of this study was to perform a systematic review and metaanalysis to evaluate clinical characteristics of patients with metastatic PPGL and reported mortality rates. We also sought to identify predictive features correlating with shorter survival in patients with this rare disease.
| MATERIALS AND METHODS

| Eligibility criteria
This study was performed based on a protocol that was designed in advance. The results of this review are reported according to PRISMA statement (preferred reporting items for systematic reviews and meta-analysis). 13 We searched for original prospective and retrospective comparative and noncomparative studies that enrolled patients with metastatic PPGL (as defined by authors of original studies).
| Inclusion and exclusion criteria
We included studies that described at least 20 patients with metastatic PPGL and reported baseline characteristics and follow-up data.
Eligible studies were not restricted to any language. In case of multiple studies describing an overlapping cohort of patients, only the study which comprised the largest number of subjects and/or the longest duration of follow-up was included for this review. We included studies whether they were published or not. We excluded all nonoriginal research studies and case reports. Because highly selected cohorts can overestimate or underestimate mortality rate, we also excluded studies reporting on a selected group of patients with metastatic PPGL (eg, only patients with bone metastases or only those undergoing chemotherapy).
| Data Sources and Search Strategies
A comprehensive search of several databases from each database's inception to December 9, 2016, in any language, was conducted (Data S1). Experts in the field were consulted and the references from primary studies were scanned to identify studies missed by the search strategy. The actual strategy is available in the appendix.
| Selection of studies
All studies obtained from the search were entered into reference manager software (EndNote). Reviewers (O.H, L.G., J.S.) working independently and in duplicate reviewed all titles and abstracts of the identified studies and selected full-text manuscripts for eligibility.
Many of the identified studies retrieved by our search were nonrelevant or nonoriginal and were excluded at this phase. Full-text screening was then performed in duplicate to assess eligibility for final inclusion. Disagreements at full-text screening were resolved by consensus or referral to the full text of the study.
| Data extraction and management
Potentially relevant studies were retrieved for detailed assessment.
Working independently and in duplicate, four reviewers (O.H., L.G., J.S and Q.Y.) used a standardized data collection form that was developed based on the protocol to extract information from each eligible study. Disagreements between reviewers were resolved by consensus or referral to the full text of the study.
For all included studies, the following data were extracted first author, year of publication, study design, setting (country, referral centre, database), population studied, number of subjects with metastatic PHEO and PGL, genetic mutation status, duration of follow-up, age at diagnosis of primary tumour and metastatic spread, functional status (defined by elevated urine or plasma catecholamines and/or metanephrines), maximal size of primary tumour, location of metastases, systemic and regional treatments, overall survival and 5-and 10-year survival rates. The outcomes of interest were focused on factors associated with shorter survival and higher mortality risk.
| Methodological quality and risk of bias assessment
The present meta-analysis is based on observational studies. Risk of bias and quality of each study were assessed by reviewers working independently and in duplicate using a modified Newcastle-Ottawa tool, which included assessment of the following: (i) how the sample represented the population of interest, (ii) how the data on metastatic PPGL were collected, (iii) sufficient follow-up period for the outcomes to occur (at least 5 years of follow-up); (iv) adequacy of follow-up (the proportion of patients assessed at the completion of the study); and (v) how the outcome was assessed. Elements of risk of bias assessment were used to explore potential heterogeneity.
Disagreements were resolved by consensus or by referring to the full text of the study. Determination of exposure (baseline characteristics and survival outcomes) was adequately reported in thirteen studies.
| Statistical analysis: summary measures and synthesis of results
We conducted a meta-analysis using the random-effects model to pool estimates from the included studies. Categorical data are presented as number (percentages). Continuous data are presented as mean ± SD. We calculated the cumulative incidence of mortality at 5, 10 and overall (longest follow-up) years for patients with PHEO, PGL, skull base and neck PGL, and SDHB-positive tumours.
We also assessed the effects of synchronous vs metachronous metastasis and male vs female sex on mortality risk. All statistical analyses were performed using Stata v14.0 (StataCorp. 2015.
Stata Statistical Software: Release 14. College Station, TX, USA:
StataCorp LP).
We used the I 2 statistic to assess for heterogeneity across individual studies and to estimate the percentage of total betweenstudy variation (ranging from 0% to 100%). 14 I 2 values of 25%, 50% and 75%, respectively, indicate low, moderate and high inconsistency across studies (heterogeneity) not explained by chance.
Heterogeneity was explored by use of stratification. Given the expected clinical heterogeneity and within-study variability, a randomeffects model was used.
| RESULTS
| Study selection
The initial search yielded 804 unique records for title and abstract screening; of these, 28 studies were selected for detailed assessment ( Figure 1 ). After full-text assessment, eight studies comprised a population already described in the publications included in our review; they were excluded because they described the smaller sample sizes and/or shorter duration of follow-up. Finally, a total of 20 studies were included in the present analysis. Eighteen studies were written in English, one in French and one in Chinese (all familiar to authors). Of these, only 13 studies contained sufficient data to be included in the quantitative meta-analysis.
| Risk of bias assessment
Characteristics of the risk of bias assessment are shown in Figure 2 .
All studies were observational and were of moderate-to-high risk of bias. Samples were not sufficiently representative in most studies (10 of 13). Most of the included studies had insufficient or unclear Number of patients who had negative SDHB mutation testing.
T A B L E 1 (Continued) duration of follow-up. Outcomes were adequately reported in all 13 studies. A clear description of how metastatic PPGL was defined and diagnosed was used in all articles.
| Study characteristics
Individual study characteristics are shown in Table 1 . Included studies were published between 1992 and 2016. Nineteen studies were classified as retrospective cohort studies, and one was classified as an inception cohort study. The studies were mostly conducted in Europe (n = 9), Asia (n = 6), and the USA (n = 5). In 2 manuscripts, only metastatic PPGL originating from the skull base and neck were studied; in 3 studies, only metastatic PHEOs were assessed; in 2 studies, only patients with genetic mutation testing were studied.
As expected, studies used different definitions of metastatic PPGL. In 11 studies, the diagnosis was made when metastases were present in nonchromaffin sites in accordance with the World Health
Organization (WHO) classification criteria of endocrine tumours. 15, 16 In 2 studies, metastatic PPGL was defined as the presence of distant metastases, local invasion 17 or histological features (PHEO of the Adrenal gland Scaled Score). 18 We were not able to exclude data of individual patients with local invasion or histological features from the study cohort. However, as the presence of metastases met our inclusion criteria for defining metastatic PPGL, we decided to include these studies for our review.
| Descriptive analysis of baseline characteristics
Twenty studies were qualitatively analysed for baseline characteristics of patients with metastatic PPGL. A total of 1338 patients were described ( Table 2) . Of these, distinction between PPGL was available in 1296 patients with 685 (52.9%) metastatic PHEO and 611 (47.1%) metastatic PGL. The patients were followed for a mean of 6.3 ± 3.2 years (range of means, 2.2-13.7 years).
Eight studies reported on genetic testing of patients with metastatic PPGL. 12, [19] [20] [21] [22] [23] [24] [25] In 3 studies (n = 228), absence of SDHB mutation was confirmed by genetic testing in all patients and the rate of SDHB mutation in this selected cohort was 59.6%. 19, 20, 25 In the other 5 studies, SDHB-negative patients were those who (i) tested negative for Turner syndrome 18 and 1 MEN1.
12
Mean age at primary tumour diagnosis was 43.9 ± 5.2 years for the entire population, 46.5 ± 5.0 years in patients with PHEO and 43.85 ± 5.2 years in patients with PGL. SDHB-positive patients were diagnosed with primary tumour at a mean age of 34.9 ± 4.6 years, and SDHB-negative patients were diagnosed at a mean age of 40.5 ± 0.7 years. Mean time to development of metastases was 3.6 ± 1.9 years. In studies where onset of metastases was reported, synchronous metastases were noted in 215 of 532 patients (40.4%).
Similarly, in studies where presenting symptoms were described, ad- 
| Mortality of patients with metastatic PPGL: meta-analysis
Results of the meta-analysis, stratified by the type of population, are shown in Figure 3 . All analyses were performed with a randomeffects model. Overall, 5-and 10-year mortality rates of patients with metastatic PPGL ranged 43%-63% (11 studies; n = 1047), 24%-51% (7 studies; n = 738) and 17%-42% (2 studies; n = 55), respectively. Overall and 5-year mortality rates in patients with PGL were 46% (95% CI, 18%-75%; 3 studies; n = 309) and 22% (95% CI, 17%-27%; 2 studies, n = 246), respectively. Overall and 5-year mortality rates in patients with metastatic PHEO were 53% (95% CI, 42%-63%; 5 studies; n = 449) and 42% (95% CI, 37%-48%; 3 studies; n = 349), respectively. Overall and 5-year mortality rates in patients with metastatic skull base and neck PGL reported in studies ranged 34%-56% (2 studies; n = 84) and 27%-48% (2 studies; n = 84), respectively. For patients with a SDHB mutation, overall mortality ranged 35%-55% (2 studies; n = 96). There was substantial heterogeneity (I 2 values over 50%) in analyses of overall and 5-year mortality.
Factors associated with higher relative risk (RR) of mortality were as follows: male sex (RR 1.50; 95% CI, 1.11-2.02) and synchronous metastases (RR 2.43; 95% CI, 1.01-5.85; Figure 4 ). These analyses were less heterogeneous.
| DISCUSSION
| Principal findings
The present systematic review and meta-analysis aimed to assess baseline characteristics and outcomes of patients with metastatic PPGL. Over a third of the patients had a SDHB germline mutation and were younger at primary tumour diagnosis, compared with SDHB-negative patients. The majority of metastatic PPGL tumours were functional and were associated with adrenergic signs and symptoms. More than 40% of patients presented with synchronous metastases.
We found that the 5-and 10-year mortality rates for patients with metastatic PPGL were 37% and 29%, respectively. We also showed that male sex and synchronous metastases were associated with shorter survival and worse outcomes. These data indicate that outcomes of patients with metastatic PPGL are heterogeneous and widely variable, possibly related to the referral bias and duration of follow-up.
SDHB mutations are thought to be highly associated with metastatic PPGL, with rates of developing metastases up to 50%-90% in some studies. 1, 12, 19, [30] [31] [32] Previous studies have also reported that SDHB mutation was associated with shorter survival rates than other PPGL types. Categorical data presented as number (percentages). Continuous data presented as mean ± SD.
a SDHB-negative patients defined as those with: a) negative genetic testing for a SDHB mutation, b) positive testing for other mutations, c) clinical criteria for NF1, or d) no genetic testing data. Note: We used this definition for all analyses reported in the table.
b SDHB-negative patients defined as those with negative genetic testing for a SDHB mutation or presence of other genetic mutation; genetic evaluation data provided in all patients in cited studies. c Total number of patients with PHEO and PGL in cited studies, respectively. Total number of patients with SDHB mutation in cited studies. e As defined by cited studies.
T A B L E 2 Description of included patients
F I G U R E 3 Meta-analysis of mortality in patients with metastatic phaeochromocytoma (PHEO) and paraganglioma (PGL) (PPGL). The size of the boxes is proportional to the weight of each study. NR, not reported [Colour figure can be viewed at wileyonlinelibrary.com] and referral bias. Although we were not able to analyse the risk of mortality in patients with SDHB mutations, overall mortality of this cohort was 45%. By excluding studies that sampled <20 patients with metastatic PPGL and seeking to analyse consecutive patients, the results from our meta-analysis showed that the pooled survival estimation in SDHB mutation carriers is higher than previously appreciated. Therefore, with the results of this study, it is possible to inform patients with metastatic PPGL more adequately concerning their prognosis.
| Limitations
The 20 studies showed a high risk of bias and were inadequate for The mortality of patients with metastatic PPGL could have been misrepresented because of insufficient follow-up in some studies. As most studies included patients with manifested disease, of whom a substantial proportion were in tertiary care centres, we assume that most included index cases with a higher than average risk of harbouring aggressive metastatic PPGL. Hence, this referral bias might also overestimate the mortality risk of metastatic PPGL. Although our results suggest that SDHB-negative tumours were larger than SDHBpositive tumours, the results of such descriptive statistics can be due to chance.
It was unclear in the majority of studies how the metastatic PPGL cases were selected. Most studies reported on a selected nonconsecutive group of patients with metastatic PHEO and/ or PGL, had unclear number of patients lost to follow-up and allowed insufficient duration of follow-up for outcomes to occur.
Additionally, 2 studies recruited subjects from national and international registries. 9, 10 Although these databases are typically well validated for epidemiological and clinical studies on cancers, [34] [35] [36] some data are inherently limited, such as patient comorbidities, sites of metastases and pertinent biochemical and genetic studies (not collected in SEER).
We were able to quantitatively analyse 13 cohort studies, with follow-up durations ranging from 2.2 and 13.7 years. The paucity of cohort studies with a long-term follow-up duration poses a risk of overrepresentation of patients with rapidly progressive disease and thus overestimation of mortality from metastatic PPGL. Of note, the 10-year mortality rate appeared lower than the 5-year mortality rate, signifying a substantial bias in patient selection and lack of sufficient follow-up. The paucity of genetic information is probably related to the fact that many genetic mutations (including SDHx gene mutations) have only been described quite recently. However, it is reported that metastatic disease can occur more than 20 years after initial diagnosis of primary tumour. 37, 38 The lack of long-term follow-up in the 2 included cohort studies (metastatic PPGL with overall survival 
| Generalizability of study results
Studies assessing the survival of patients with metastatic PPGL were included in the meta-analysis. However, most studies included patients from international registries, while the accurate outcomes and survival rates may vary in different countries. Furthermore, these registries mostly comprised symptomatic patients treated in tertiary care centres and were largely retrospective in nature, with registration of patients at a single point in time and little or no entry of follow-up data. These selection mechanisms prohibit simple generalizations of the study results.
| Recommendations for future research
This meta-analysis assessed the overall, 5-and 10-year mortality rates of patients with metastatic PPGL carrying specific risk factors (male sex, synchronous metastases). However, only one study was conducted in a prospective manner. Heterogeneous reporting of variables and length of follow-up in the available studies on metastatic PPGL does not allow for a more in-depth or additional analysis of variables associated with more aggressive disease. As metastatic PPGL is a rare disorder, we suggest that it would be of great benefit to perform a large multicentre retrospective study on nonselected patients with metastatic PPGL to include detailed characteristics of clinical, biochemical, imaging and genetic variables and evaluate outcomes.
Multicentre collaboration enables a larger sample size of patients with metastatic PPGL and allows a subgroup analysis in this heterogeneous disorder. Data from a well-designed, large sample size, retrospective study will be extremely valuable not only to determine an evidencebased monitoring approach for such patients, but also to design a multicentre longitudinal long-term prospective observational study after agreement on such an approach.
| CONCLUSION
In conclusion, the present study shows that the mortality of patients with metastatic PPGL is highly variable, depending on the presence of risk factors. Overall pooled 5-and 10-year mortality rates were 37% and 29%. Male sex and synchronous metastases were associated with increased mortality risk. The mortality of patients with metastatic PPGL varied considerably in the included studies due to methodological differences, including selection bias. Past studies have been inadequate for assessing outcomes of patients with metastatic PPGL.
Further research is indicated to provide accurate prognostic information for patients with metastatic PPGL.
